Pre-Test Addressing the Complexities of Vitiligo: Targeted Strategies to Improve Quality of Life Pre-Test In the US, approximately what percentage of individuals with vitiligo are estimated to be undiagnosed? 20% 30% 40% 50% Unsure In two phase 2 trials, which of the following demonstrated improved repigmentation of nonsegmental vitiligo lesions through 52 weeks of follow-up? Baricitinib Ifidancitinib Ruxolitinib Tofacitinib Unsure Which of the following cytokines is involved in JAK/STAT initiation and contributes to vitiligo pathophysiology? IFN-γ IL-17 IL-12 TNF-α Unsure How confident are you in your ability to implement strategies to improve recognition and optimal multidisciplinary care for vitiligo management? Very Confident Confident Somewhat confident Not very confident Not at all confident
